Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Merck
Mallinckrodt
McKesson
Moodys

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIMIDUCID


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Rimiducid

Trial ID Title Status Sponsor Phase Summary
NCT01744223 ↗ Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting Bellicum Pharmaceuticals Phase 1/Phase 2 This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the patient, the T cells start to react against the tissues (called "graft versus host" disease, GVHD), the T cells can be destroyed.
NCT02065869 ↗ Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant Active, not recruiting Bellicum Pharmaceuticals Phase 2 This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (Graft versus host disease).
NCT02477878 ↗ Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting Bellicum Pharmaceuticals Phase 1 A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will be investigated for the treatment of aGvHD after BPX-501 T cell infusion to determine a dose that can mitigate GvHD and preserve the graft versus leukemia effect.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Rimiducid

Condition Name

Condition Name for
Intervention Trials
Myelodysplastic Syndromes 6
Acute Lymphoblastic Leukemia 5
Multiple Myeloma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Myelodysplastic Syndromes 9
Preleukemia 7
Leukemia, Myeloid, Acute 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rimiducid

Trials by Country

Trials by Country for
Location Trials
United States 81
Italy 4
United Kingdom 3
Saudi Arabia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Texas 9
Washington 8
Tennessee 7
New York 7
California 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rimiducid

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 1
Phase 1/Phase 2 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 6
Active, not recruiting 5
Withdrawn 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rimiducid

Sponsor Name

Sponsor Name for
Sponsor Trials
Bellicum Pharmaceuticals 14
Poseida Therapeutics, Inc. 4
National Cancer Institute (NCI) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 18
Other 8
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
AstraZeneca
Dow
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.